Teyi Pharmaceutical Group's low P/E ratio is seen as reasona...

Teyi Pharmaceutical Group's low P/E ratio is seen as reasonable given its expected underperformance and shrinking earnings outlook. Shareholders accept this, anticipating no pleasant surprises in future earnings. A strong share price rise seems unlikely under these conditions.